# Abbott Laboratories (ABT) fundamentals

Data as of 2026-11-04. NYSE, United States. Sector: Healthcare / Medical Devices & Supplies. Price $109.40, market value $189.3 billion.

## Valuation
- **P/E (trailing): 40.7×** (5-yr avg 27.6×, 3-yr avg 26.4×). Abbott Laboratories trades at 40.7× trailing earnings, well above its own five-year average of 27.6×: investors are paying up relative to the company's past. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 18.4×, lower than trailing, so analysts expect earnings to grow.
- **Price / sales: 4.2×**. Each dollar of revenue is priced at 4.2×.
- **Price / book: 3.7×**. The shares trade at 3.7× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: 3.9%** (5-yr avg 3.5%). Free cash flow equals 3.9% of the market value, in line with its five-year average of 3.5%.
- **Earnings yield: 2.5%**. The inverse of the P/E: 2.5% of the price is earned each year.

## Profitability
- **Operating margin: 17.1%**. 17.1% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: 14.7%**. 14.7% of each dollar of sales reaches the bottom line.
- **Return on equity: 12.5%**. 12.5% on shareholders' equity is solid.
- **Return on invested capital: 10.8%**. Return on all capital, debt included, is 10.8%.
- **Return on assets: 7.2%**. Each dollar of assets produces 7.2% of profit.

## Growth
- **Revenue growth (1 yr): 5.7%** (3-yr 0.5%/yr, 5-yr 5.1%/yr). Revenue grew 5.7% over the last year, against 5.1% a year compounded over five years.
- **EPS growth (1 yr): -51.3%** (3-yr -1.6%/yr, 5-yr 8.3%/yr). Earnings per share fell 51.3%, slower than revenue, so margins compressed.
- **Free-cash-flow growth (3 yr): -1.8%/yr**. Free cash flow has compounded at -1.8% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.25**. Debt is 0.25 times equity: a conservative balance sheet.
- **Current ratio: 1.58** (quick 1.58). Current assets cover the next year's liabilities 1.58 times.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 2.30%** ($2.52 per share, trailing). Abbott Laboratories yields 2.30%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 63%** (57% of free cash flow). 63% of earnings goes out as dividends, leaving room to keep raising it.
- **Consecutive years of increases: 12**. 12 straight years of increases, a record that survived at least one recession.
- **Dividend growth (5 yr): 10.4%/yr** (1-yr 7.3%). The dividend has compounded at 10.4% a year over five years, doubling roughly every 7 years at that pace.

## Analyst view
- **Analyst consensus: buy** (26 analysts). 26 analysts cover Abbott Laboratories; the consensus is buy, with an average price target of $118.52 (+8% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -10.0%** (YTD -11.1%, 3-mo 3.7%). The shares are down 10.0% over twelve months including dividends.
- **From 52-week high: -17.1%** (33.5% above the low). Trading 17% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 65**. An RSI of 65 is neutral.
- **Beta (1 yr): -0.02** (volatility 28%). Beta of -0.02 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ABT · Page: https://foliofundamentals.com/stocks/abt

Not investment advice.